| Host: |
Rabbit |
| Applications: |
WB/ELISA |
| Reactivity: |
Human/Rat/Mouse |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Rabbit polyclonal antibody anti-Cleaved-Caspase-1-N120 (101-150 aa) is suitable for use in Western Blot and ELISA research applications. |
| Clonality: |
Polyclonal |
| Conjugation: |
Unconjugated |
| Isotype: |
IgG |
| Formulation: |
Liquid in PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide. |
| Purification: |
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. |
| Concentration: |
1 mg/mL |
| Dilution Range: |
WB 1:500-1:2000ELISA 1:20000 |
| Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Gene Symbol: |
CASP1 |
| Gene ID: |
834 |
| Uniprot ID: |
CASP1_HUMAN |
| Immunogen Region: |
101-150 aa |
| Specificity: |
Cleaved-Caspase-1 p20 (N120) Polyclonal Antibody detects endogenous levels of fragment of activated Caspase-1 p20 protein resulting from cleavage adjacent to N120. |
| Immunogen: |
The antiserum was produced against synthesized peptide derived from the human Caspase 1 at the amino acid range 101-150 |
| Post Translational Modifications | The two subunits are derived from the precursor sequence by an autocatalytic mechanism. Ubiquitinated via 'Lys-11'-linked polyubiquitination. Deubiquitinated by USP8. Cleavage in the interdomain linker region is required to induce pyroptosis. |
| Function | Thiol protease involved in a variety of inflammatory processes by proteolytically cleaving other proteins, such as the precursors of the inflammatory cytokines interleukin-1 beta (IL1B) and interleukin 18 (IL18) as well as the pyroptosis inducer Gasdermin-D (GSDMD), into active mature peptides. Plays a key role in cell immunity as an inflammatory response initiator: once activated through formation of an inflammasome complex, it initiates a pro-inflammatory response through the cleavage of the two inflammatory cytokines IL1B and IL18, releasing the mature cytokines which are involved in a variety of inflammatory processes. Cleaves a tetrapeptide after an Asp residue at position P1. Also initiates pyroptosis, a programmed lytic cell death pathway, through cleavage of GSDMD. In contrast to cleavage of interleukins IL1B and IL1B, recognition and cleavage of GSDMD is not strictly dependent on the consensus cleavage site but depends on an exosite interface on CASP1 that recognizes and binds the Gasdermin-D, C-terminal (GSDMD-CT) part. Cleaves and activates CASP7 in response to bacterial infection, promoting plasma membrane repair. Upon inflammasome activation, during DNA virus infection but not RNA virus challenge, controls antiviral immunity through the cleavage of CGAS, rendering it inactive. In apoptotic cells, cleaves SPHK2 which is released from cells and remains enzymatically active extracellularly. Isoform Delta: Apoptosis inactive. Isoform Epsilon: Apoptosis inactive. |
| Protein Name | Caspase-1Casp-1Interleukin-1 Beta ConvertaseIl-1bcInterleukin-1 Beta-Converting EnzymeIceIl-1 Beta-Converting EnzymeP45 Cleaved Into - Caspase-1 Subunit P20 - Caspase-1 Subunit P10 |
| Database Links | Reactome: R-HSA-168638Reactome: R-HSA-448706Reactome: R-HSA-5620971Reactome: R-HSA-6803207Reactome: R-HSA-844456Reactome: R-HSA-844615Reactome: R-HSA-844623Reactome: R-HSA-9008059Reactome: R-HSA-9660826Reactome: R-HSA-9692916 |
| Cellular Localisation | CytoplasmCell Membrane |
| Alternative Antibody Names | Anti-Caspase-1 antibodyAnti-Casp-1 antibodyAnti-Interleukin-1 Beta Convertase antibodyAnti-Il-1bc antibodyAnti-Interleukin-1 Beta-Converting Enzyme antibodyAnti-Ice antibodyAnti-Il-1 Beta-Converting Enzyme antibodyAnti-P45 Cleaved Into - Caspase-1 Subunit P20 - Caspase-1 Subunit P10 antibodyAnti-CASP1 antibodyAnti-IL1BC antibodyAnti-IL1BCE antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
